Stock CABA CABALETTA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
10.19 USD +2.62% Intraday chart for Cabaletta Bio, Inc. -6.68% -55.11%
May. 15 Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 22 HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio : Corporate Presentation
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
North American Morning Briefing : Markets on Hold -2-
North American Morning Briefing : Stock Futures -2-
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
Jefferies Initiates Cabaletta Bio with Buy Rating, $36 Price Target
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CABA Stock
  4. News Cabaletta Bio, Inc.
  5. Other languages